299 A phase I/II study to evaluate EP0031 (lunbotinib), a next generation selective RET inhibitor, as monotherapy and in combination with chemotherapy, in patients with advanced RET fusion positive NSCLC

Lung Cancer 2026

View at publisher
Authors: Martin David Forster, Sanjay Popat, Debashis Sarker, Jonathan Wadsley, Amal Ibrahim, Akul Purohit, Thubeena Manickavasagar, Alfie Beard, Robin Young, Geoff Roy Fisher, Sonia Simon Serrano, Hendrik‐Tobias Arkenau
+1 more Matthew Krebs
DOI: 10.1016/j.lungcan.2026.109247
Cited by: 0
References: 2

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Mechanisms and Therapy Lung Cancer Research Studies

Publication details

Journal / source
Lung Cancer
Volume
212
Pages
109247–109247
Publication date
1 February 2026
Language
EN